miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 15, 2026

Is It Time To Reassess UPS (UPS) After Recent Parcel Demand Headlines And Mixed Returns?

View original at finance.yahoo.com
“For United Parcel Service, the model used is a 2 Stage Free Cash Flow to Equity approach, based on Free Cash Flow in the last twelve months of about $4.3b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • UPS currently scores 5 out of 6 on Simply Wall St's valuation checks

    60% confidence

  • Analysts project UPS annual Free Cash Flow to reach $9.6 billion by 2035

    60% confidence

  • United Parcel Service is undervalued by 37.8% according to DCF analysis

    60% confidence

  • UPS Free Cash Flow is estimated at $7.6 billion in 2029

    60% confidence

  • Recent headlines have focused on UPS as a bellwether for parcel volumes, labor costs and broader freight demand

    60% confidence

  • UPS Free Cash Flow is estimated at $6.1 billion in 2026

    60% confidence

  • UPS shares trade at about a 37.8% discount to intrinsic value based on DCF analysis

    60% confidence

Data points we hold from this source

United Parcel Service · free cash flow4.3 USD
United Parcel Service · intrinsic value per share166.04 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is It Time To Reassess UPS (UPS) After Recent Parcel Demand Headlines And Mixed Returns? — Source | Via News | es.VIA.NEWS